2739690-43-6
2739690-43-6
Chemical Structure
Luvometinib
Synonym(s): FCN-159
- CAS No.: 2739690-43-6
- Formula:C26H22F2IN5O4S
- Molecular Weight:665.45
InChIKey: RJFDJJABNSVLRB-UHFFFAOYSA-N
SMILES: O=C1C(F)=C(C2=C(N1C)C(C3=CC(NS(=O)(C4CC4)=O)=CC=C3)=NN(C5CC5)C2=O)NC6=CC=C(C=C6F)I
Biological Activity: Luvometinib is a mitogen-activated protein kinase (MEK) inhibitor with antitumor activity[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Luvometinib | 99.94% | Luvometinib is a mitogen-activated protein kinase (MEK) inhibitor with antitumor activity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Luvometinib-d | Luvometinib-d (FCN-159-d) is the deuterated-labeled Luvometinib (HY-159846). Luvometinib is an orally potent MEK1/2 inhibitor. Luvometinib selectively blocks the MAPK signaling pathway by forming a ternary complex with MEKase and ATP, thereby reducing the phosphorylation level of ERK. Luvometinib induces cell cycle arrest and apoptosis, and inhibits cancer cell proliferation. Luvometinib can be used in relevant research on various solid tumors including melanoma, non-small cell lung cancer, colon cancer, and acute myeloid leukemia. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
ODM-203 | 99.62% | ODM-203 is an orally active and selective FGFR/VEGFR inhibitor with IC50 values of 6, 11, 16, 5, 9, 26 and 35 nM for FGFR3/1/2 and VEGFR3/2/1/4, respectively. ODM-203 has strong anti-tumour activity and activates immune responses in the tumour microenvironment. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
JTP-70902 | JTP-70902, a p15INK4b-inductive compound, is a MEK1/2 inhibitor. JTP-70902 exhibits potent antitumor effect. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
NVS-BPTF-1 | 99.28% | NVS-BPTF-1, a chemical probe, is a selective inhibitor for bromodomain and PHD finger containing transcription factor (BPTF), with KD of 71 nM. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
IHMT-PI3Kδ-372 | 99.69% | IHMT-PI3Kδ-372 is a potent and selective PI3Kδ inhibitor with an IC50 of 14 nM. IHMT-PI3Kδ-372 shows high selectivity over other class I PI3Ks (56～83 fold) and other protein kinases. IHMT-PI3Kδ-372 can be uesd for chronic obstructive pulmonary disease (COPD) research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(R)-IHMT-PI3Kδ-372 | 99.51% | (R)-IHMT-PI3Kδ-372 (R-18) is a potent and selective PI3Kδ inhibitor with an IC50 of 19 nM. (R)-IHMT-PI3Kδ-372 (R-18) can be used in chronic obstructive pulmonary disease (COPD) research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
TAK-733 | 99.79% | TAK-733 is a potent and selective MEK allosteric site inhibitor with an IC50 of 3.2 nM. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Trametiglue | 98.81% | Trametiglue, a derivative of Trametinib (HY-10999), targets both KSR-MEK and RAF-MEK with unprecedented potency and selectivity via unique interfacial binding interactions. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Mivebresib-alkyne | Mivebresib-alkyne (Compound 25), a Mivebresib (HY-100015) derivative, can be used for BRD4 targeted PROTAC synthesis through click reaction. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
MEK-IN-7 | MEK-IN-7 (compound WX086) is potent, orally active and selective MEK inhibitor (MEK1 IC50 = 29.62 nM). MEK-IN-7 inhibits HT29 and A375 cell proliferation with IC50s of 0.62 and 0.40 nM. MEK-IN-7 inhibits tumor growth in a HL-29 xenograft mouse model. MEK-IN-7 can be used for melanoma and colon cancer research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
PI3K/PIKK-IN-2 | PI3K/PIKK-IN-2 (Compound 2) is an inhibitor of PI3K/PIKK. PI3K/PIKK-IN-2 can be used in preparing antibody-drug conjugates (ADCs). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
